At a glance
- See how many people have gotten a COVID-19, flu, or RSV vaccine so far this season.
- See how many people plan to get one.
- Find out who CDC recommends should get each vaccine.
- Learn how the numbers are collected: weekly national surveys, updated every week.
COVID-19 Vaccine
COVID-19 vaccines are effective at protecting people from getting seriously ill, being hospitalized, and dying. Vaccination remains the safest strategy for avoiding hospitalizations, long-term health outcomes, and death.
CDC recommends COVID-19 vaccines:
- For all adults ages 18 years and older
- For all children ages 6 months–17 years who are moderately to severely [[tooltip:immunocompromised|A weakened immune system that makes it harder to fight infections. This can be caused by certain conditions or medications.]]
- For all other children ages 6 months-17 years, caregivers should ask a healthcare provider about the COVID-19 vaccine
The FDA approved the COVID-19 vaccines for the 2026-27 fall and winter virus season in August 2026.
COVID-19 Vaccination in the United States
This chart shows the weekly total percent of adults and children vaccinated with the 2025-26 COVID-19 vaccine. Refer to data notes for more details.
COVID-19 Vaccination Intent in the United States
This chart shows the weekly total percent of adults and children who plan to get or have already gotten vaccinated with the 2025-26 COVID-19 vaccine. Refer to data notes for more details.
Flu Vaccine
Each year's flu vaccine is designed to protect you from the flu viruses experts think will spread the most that season. Even when the viruses are different than expected, vaccination still protects against severe illness, hospitalization, and death.
CDC recommends that all people aged 6 months and older receive a seasonal flu vaccine. See additional data »
Flu Vaccination in the United States
This chart shows the weekly total percent of adults and children vaccinated with 2025-26 seasonal flu vaccine. Refer to data notes for more details.
Flu Vaccination Intent in the United States
This chart shows how many adults and children plan to get a flu shot and how many have already gotten one, for the 2025-2026 flu season. Refer to data notes for more details.
RSV Vaccine
The RSV vaccine can prevent infection or illness in the lungs, like bronchitis or pneumonia caused by respiratory syncytial virus (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms but may be especially serious for infants and older adults.
CDC recommends a single dose of RSV vaccine for all adults 75 years and older. The vaccine is also recommended for adults 50–74 who are at increased risk of severe RSV. To prevent severe RSV disease in infants, CDC recommends either maternal RSV vaccination or infant immunization with an infant RSV antibody.
RSV Vaccination in the United States
This chart shows the weekly total percent of adults 75 years and older who are vaccinated with RSV vaccine. Refer to data notes for more details.
RSV Vaccination Intent in the United States
This chart shows the weekly total percent of adults 75 years and older who plan to get or have already gotten vaccinated with RSV vaccine. Refer to data notes for more details.
Data Notes
- Source: National Immunization Survey-Flu (NIS-Flu).
- Additional information available at: About the National Immunization Surveys.
- Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week (combined with all previous interviews). Estimates for vaccination intent are based on interviews conducted that week and are adjusted to the cumulative vaccination coverage estimate for that week.
- Confidence Intervals (CI) describe the level of uncertainty around an estimate because a sample was taken via a survey. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% CI, if the sampling method is repeated many times, the value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
- COVID-19 vaccination coverage estimates presented in this report represent uptake or intent for uptake of the 2025-26 COVID-19 vaccine. For children ≥2 years, up-to-date with the 2025-2026 COVID-19 vaccine is defined as receipt of at least one vaccination since September 2025; for children <2 years, up-to-date status is defined based on the current recommendations that also take into account number of doses and brand of vaccine. Up-to-date status was determined by survey questions on month and year of most recent COVID-19 vaccine, and, for children <2 years, total number of COVID-19 vaccinations received and brand of most recent COVID-19 vaccine.
- Estimates from the NIS-Flu may differ from estimates based on other data sources, and are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self or parental reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
- Source: National Immunization Survey-Fall Respiratory Virus Module (NIS-FRVM)
- Additional information available at: About the National Immunization Surveys.
- Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week, combined with all previous interviews.
- Estimates for vaccination intent are based on interviews conducted that week and are adjusted to the cumulative vaccination coverage estimate for that week.
- Confidence Intervals (CI) describe the level of uncertainty around an estimate because a sample was taken via a survey. 95% CIs represent the range of values that would result if the data collection had been repeated many times. For a 95% CI, if the sampling method is repeated many times, the value would fall within this interval at least 95% of the time. Wider CIs reflect larger random error in estimates resulting from survey sampling.
- COVID-19 vaccination coverage estimates presented in this report represent uptake or intent for uptake of the 2025-26 COVID-19 vaccine.
- Estimates for RSV vaccination among adults ages 50-74 at increased risk of severe RSV disease are shown on RSVVaxView.
- Estimates from the NIS-FRVM may differ from estimates based on other data sources and are subject to errors resulting from incomplete sample frame (exclusion of households without cell phones), selection bias (survey respondents may be more likely to be vaccinated than non-respondents), and errors in self or parental reported vaccination status. Estimates are weighted to selected sociodemographic characteristics of the U.S. population to reduce possible bias from incomplete sample frame and selection bias.
This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.
The information on this page was last reviewed by subject matter experts to ensure accuracy.